Moreover, preclinical research has shown neuroprotective effects by lowering tau hyperphosphorylation and amyloid-beta aggregation, therefore pointing to its potential for modifying the course of Alzheimer’s disease (Dan et al. 2024). The gene discussed is MAPT; the disease is Alzheimer disease.